No Data
No Data
Yabao Pharmaceutical (600351.SH) plans to pay $0.15 per share in 2023, excluding interest on May 30
Yabao Pharmaceutical (600351.SH) announced that the company plans to distribute a cash dividend of 0.15 yuan per share in 2023...
Yabao Pharmaceutical Group's (SHSE:600351) Performance Is Even Better Than Its Earnings Suggest
Even though Yabao Pharmaceutical Group Co., Ltd's (SHSE:600351) recent earnings release was robust, the market didn't seem to notice. We think that investors have missed some encouraging factors unde
Yabao Pharmaceutical (600351.SH) released 2023 annual results, with net profit of 200 million yuan, an increase of 90.71% over the previous year
According to Zhitong Finance App, Yabao Pharmaceutical (600351.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 2,910 billion yuan, an increase of 7.05%; net profit attributable to shareholders of listed companies was 200 million yuan, an increase of 90.71% year on year; net profit attributable to shareholders of listed companies deducted 180 million yuan from non-recurring profit and loss, an increase of 106.11% year on year; basic earnings per share were 0.2615 yuan/share. The company's 2023 profit distribution plan is: cash bonuses will be distributed to all shareholders for every 10 shares based on the company's total share capital on the day the equity distribution was implemented
Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules
Yabao Pharmaceutical Group (SHA:600351) obtained a drug registration certificate from China's National Medical Products Administration for montelukast sodium granules, according to a Tuesday filing to
Yabao Pharmaceutical (600351.SH): Montelukast sodium granules obtain drug registration certificate
Gelonghui April 15 丨 Yabao Pharmaceutical (600351.SH) announced that Yabao Pharmaceutical Sichuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the “Drug Registration Certificate” for montelukast sodium granules approved and issued by the State Drug Administration. The main products of montelukast sodium granules are suitable for the prevention and long-term treatment of asthma in children over 1 year of age, including preventing daytime and nighttime asthma symptoms, treating asthmatics sensitive to aspirin, and preventing exercise-induced bronchospasm; reducing symptoms caused by allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in children aged 2 to 5).
Yabao Pharmaceutical (600351.SH) has spent 322 million yuan to buy back 6.49% of the shares
Yabao Pharmaceutical (600351.SH) issued an announcement. As of March 31, 2024, the company passed centralized bidding...
No Data